Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05040334
Other study ID # Cairo University Obygyn
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 1, 2021
Est. completion date May 1, 2022

Study information

Verified date March 2022
Source Cairo University
Contact Marwa Mo Eid, Ass.professor
Phone 01001225079
Email marwameid2014@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the role of antibiotic prophylaxis in the surgical management of miscarriage.


Description:

Patients will be randomized to receive either prophylactic antibiotic [a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)] or placebo using identical sealed envelopes.Included cases are those with early miscarriage (within the first trimester 12 6/7 weeks of gestation) , missed or incomplete miscarriage, undergoing surgical management will be included in the study. Technique: The investigators will prepare 138 identical envelops, half of them filled with a label group(1) who are the group to receive the antibiotic prophylaxis with all instruction details, while the other half filled with a label identifying ( group 2) who are the placebo group. All envelops will be prepared by the investigator and sealed before starting enrollment. After enrollment, each participant will be allowed to choose one envelop to determine to which group the patient will be assigned to.


Recruitment information / eligibility

Status Recruiting
Enrollment 138
Est. completion date May 1, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion criteria: - Maternal age :18-35 years - Gestational age: up to 12 6/7 weeks of gestation (confirmed by a reliable date for the last menstrual period or /and 1st trimester ultrasound scan). - Singleton miscarriage - Type of miscarriage: Incomplete or Missed miscarriage - Surgical evacuation will be done within 2 weeks of diagnosis of miscarriage . Exclusion criteria: - Maternal age: younger than 18 years - Induced miscarriage of pregnancy - Septic miscarriage - Evidence of infection - Morbid obesity (BMI=40kg/m2) - Allergy to prophylactic antibiotics (i.e., doxycycline or metronidazole) - Antibiotics use within 7 days before randomization

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Group 1: Antibiotic receiving group
Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation

Locations

Country Name City State
Egypt Department of Obstetrics and Gynecology, Kasr Al-Ainy University Hospital, Cairo University. Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of pelvic infection after surg ical evacuation of miscarriage with use of antibiotic prophylaxis. White cell count >12 *10^9 cells / L by CBC 2 weeks from surgery
Secondary Change in the risk of severe puerperal sepsis following the surgical procedure Signs of puerperal sepsis in form of puerperal pyrexia >38 C and/or purulent vaginal discharge 2 weeks from surgery
See also
  Status Clinical Trial Phase
Withdrawn NCT04230746 - Effect of Antibiotics on Urinary Microbiome Early Phase 1
Recruiting NCT04705259 - A Multimodal Intervention to Optimise Antimicrobial Use in Residential Aged Care Facilities (ENGAGEMENT Study) N/A
Not yet recruiting NCT04980170 - Clindamycin Versus Amoxicillin With Clavulanic Acid in Prevention of Early Dental Implants Failure Early Phase 1
Completed NCT03622008 - To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) Phase 1
Enrolling by invitation NCT05020418 - De-Implementation of Inappropriate Antimicrobial Use After Cardiac Device Procedures N/A
Enrolling by invitation NCT05224687 - Utility Assessment of a Pharmacy-to-Dose Daptomycin